BioXcel Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BTAI Nasdaq 2836 www.bioxceltherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioXcel Therapeutics, Inc.

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - May 28th, 2026 5:00 am
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - May 15th, 2026 6:15 am
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - May 15th, 2026 5:00 am
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates - May 14th, 2026 6:45 am
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 5:05 pm
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - May 4th, 2026 8:00 am
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns - Apr 17th, 2026 7:36 am
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - Apr 17th, 2026 5:00 am
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Apr 13th, 2026 10:11 am
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Apr 8th, 2026 5:00 am
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - Apr 1st, 2026 5:00 am
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Mar 29th, 2026 10:04 am
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting - Mar 27th, 2026 5:00 am
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Mar 12th, 2026 12:13 pm
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - Mar 11th, 2026 2:20 pm
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - Mar 10th, 2026 12:36 pm
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal - Mar 5th, 2026 5:00 am
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia - Feb 19th, 2026 5:00 am
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting - Feb 12th, 2026 5:00 am
Rigel Appoints Michael P. Miller to the Board of Directors - Feb 3rd, 2026 6:05 am